Identification of novel methylation markers in hepatocellular carcinoma using a methylation array

Journal of Korean Medical Science

Volumn 25, Issue 8, 2010, Pages 1152-1159

  Shin, So Hyun ^a   Kim, Baek Hui ^b   Jang, Ja June ^c   Suh, Kyung Suk ^c   Kang, Gyeong Hoon ^a,c  

^a Seoul National University   (South Korea)

^b Korea University College of Medicine   (South Korea)

^c Seoul National University College of Medicine   (South Korea)

Author keywords

Bead array; Carcinoma; CpG Islands; DNA methylation; Hepatocellular

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTINEOPLASTIC ANTIMETABOLITE; AZACITIDINE; DRUG DERIVATIVE; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; HOMEODOMAIN PROTEIN; INTERFERON REGULATORY FACTOR; IRF5 PROTEIN, HUMAN; NEUROPEPTIDE Y; TNFRSF10C PROTEIN, HUMAN; TRANSCRIPTION FACTOR HOXA9; TUMOR NECROSIS FACTOR DECOY RECEPTOR;

ARTICLE; CPG ISLAND; DNA METHYLATION; DNA MICROARRAY; GENE EXPRESSION PROFILING; GENETICS; HUMAN; LIVER CELL CARCINOMA; LIVER TUMOR; PROMOTER REGION; TUMOR CELL LINE;

ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CPG ISLANDS; DNA METHYLATION; GENE EXPRESSION PROFILING; GPI-LINKED PROTEINS; HOMEODOMAIN PROTEINS; HUMANS; INTERFERON REGULATORY FACTORS; LIVER NEOPLASMS; NEUROPEPTIDE Y; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROMOTER REGIONS, GENETIC; TUMOR NECROSIS FACTOR DECOY RECEPTORS;

EID: 77956607702     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2010.25.8.1152     Document Type: Article

References (30)

1. Saxonov S, Berg P, Brutlag DL. A genome-wide analysis of CpG dinucleotides in the human genome distinguishes two distinct classes of promoters. Proc Natl Acad Sci USA 2006; 103: 1412-7.
2. Weber M, Hellmann I, Stadler MB, Ramos L, Paabo S, Rebhan M, Schübeler D. Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome. Nat Genet 2007; 39: 457-66.
3. Li E, Beard C, Jaenisch R. Role for DNA methylation in genomic imprinting. Nature 1993; 366: 362-5.
4. Panning B, Jaenisch R. RNA and the epigenetic regulation of X chromosome inactivation. Cell 1998; 93: 305-8.
5. Esteller M. Epigenetic gene silencing in cancer: the DNA hypermethylome. Hum Mol Genet 2007; 16 Spec No 1: R50-9.
6. Baylin SB, Chen WY. Aberrant gene silencing in tumor progression: implications for control of cancer. Cold Spring Harb Symp Quant Biol 2005; 70: 427-33.
7. Teodoridis JM, Strathdee G, Brown R. Epigenetic silencing mediated by CpG island methylation: potential as a therapeutic target and as a biomarker. Drug Resist Updat 2004; 7: 267-78.
8. Calvisi DF, Ladu S, Gorden A, Farina M, Lee JS, Conner EA, Schroeder I, Factor VM, Thorgeirsson SS. Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma. J Clin Invest 2007; 117: 2713-22.
9. Tischoff I, Tannapfe A. DNA methylation in hepatocellular carcinoma. World J Gastroenterol 2008; 14: 1741-8.
10. Lou C, Yang B, Gao YT, Wang YJ, Nie FH, Yuan Q, Zhang CL, Du Z. Aberrant methylation of multiple genes and its clinical implication in hepatocellular carcinoma. Zhonghua Zhong Liu Za Zhi 2008; 30: 831-6.
11. Schuebel KE, Chen W, Cope L, Glockner SC, Suzuki H, Yi JM, Chan TA, Van Neste L, Van Criekinge W, van den Bosch S, van Engeland M, Ting AH, Jair K, Yu W, Toyota M, Imai K, Ahuja N, Herman JG, Baylin SB. Comparing the DNA hypermethylome with gene mutations in human colorectal cancer. PLoS Genet 2007; 3: 1709-23.
12. Bibikova M, Lin Z, Zhou L, Chudin E, Garcia EW, Wu B, Doucet D, Thomas NJ, Wang Y, Vollmer E, Goldmann T, Seifart C, Jiang W, Barker DL, Chee MS, Floros J, Fan JB. High-throughput DNA methylation profiling using universal bead arrays. Genome Res 2006; 16: 383-93.
13. Cho NY, Kim BH, Choi M, Yoo EJ, Moon KC, Cho YM, Kim D, Kang GH. Hypermethylation of CpG island loci and hypomethylation of LINE-1 and Alu repeats in prostate adenocarcinoma and their relationship to clinicopathological features. J Pathol 2007; 211: 269-77.
14. Christman JK. 5-Azacytidine and 5-aza-2'-deoxycytidine as inhibitors of DNA methylation: Mechanistic studies and their implications for cancer therapy. Oncogene 2002; 21: 5483-95.
15. Jones PA. Altering gene expression with 5-azacytidine. Cell 1985; 40: 485-6.
16. Yan C, Boyd DD. Histone H3 acetylation and H3 K4 methylation define distinct chromatin regions permissive for transgene expression. Mol Cell Biol 2006; 26: 6357-71.
17. Lund AH, van Lohuizen M. Polycomb complexes and silencing mechanisms. Curr Opin Cell Biol 2004; 16: 239-46.
18. Shivapurkar N, Toyooka S, Toyooka KO, Reddy J, Miyajima K, Suzuki M, Shigematsu H, Takahashi T, Parikh G, Pass HI, Chaudhary PM, Gazdar AF. Aberrant methylation of trail decoy receptor genes is frequent in multiple tumor types. Int J Cancer 2004; 109: 786-92.
19. Gehring WJ, Affolter M, Burglin T. Homeodomain proteins. Annu Rev Biochem 1994; 63: 487-526.
20. Rauch T, Wang Z, Zhang X, Zhong X, Wu X, Lau SK, Kernstine KH, Riggs AD, Pfeifer GP. Homeobox gene methylation in lung cancer studied by genome-wide analysis with a microarray-based methylated CpG island recovery assay. Proc Natl Acad Sci USA 2007; 104: 5527-32.
21. Wu Q, Lothe RA, Ahlquist T, Silins I, Trope CG, Micci F, Nesland JM, Suo Z, Lind GE. DNA methylation profiling of ovarian carcinomas and their in vitro models identifies HOXA9, HOXB5, SCGB3A1, and CRABP1 as novel targets. Mol Cancer 2007; 6: 45.
22. Hallden G, Hadi M, Hong HT, Aponte GW. Y receptor-mediated induction of CD63 transcripts, a tetraspanin determined to be necessary for differentiation of the intestinal epithelial cell line, hBRIE 380i cells. J Biol Chem 1999; 274: 27914-24.
23. Minth CD, Andrews PC, Dixon JE. Characterization, sequence, and expression of the cloned human neuropeptide Y gene. J Biol Chem 1986; 261: 11974-9.
24. Liu AJ, Furusato B, Ravindranath L, Chen YM, Srikantan V, McLeod DG, Petrovics G, Srivastava S. Quantitative analysis of a panel of gene expression in prostate cancer-with emphasis on NPY expression analysis. J Zhejiang Univ Sci B 2007; 8: 853-9.
25. Abe M, Watanabe N, McDonell N, Takato T, Ohira M, Nakagawara A, Ushijima T. Identification of genes targeted by CpG island methylator phenotype in neuroblastomas, and their possible integrative involvement in poor prognosis. Oncology 2008; 74: 50-60.
26. Pitha PM, Au WC, Lowther W, Juang YT, Schafer SL, Burysek L, Hiscott J, Moore PA. Role of the interferon regulatory factors (IRFs) in virus-mediated signaling and regulation of cell growth. Biochimie 1998; 80: 651-8.
27. Yanai H, Chen HM, Inuzuka T, Kondo S, Mak TW, Takaoka A, Honda K, Taniguchi T. Role of IFN regulatory factor 5 transcription factor in antiviral immunity and tumor suppression. Proc Natl Acad Sci USA 2007; 104: 3402-7.
28. Guenther MG, Levine SS, Boyer LA, Jaenisch R, Young RA. A chromatin landmark and transcription initiation at most promoters in human cells. Cell 2007; 130: 77-88.
29. Bernstein BE, Meissner A, Lander ES. The mammalian epigenome. Cell 2007; 128: 669-81.
30. Ohm JE, McGarvey KM, Yu X, Cheng L, Schuebel KE, Cope L, Mohammad HP, Chen W, Daniel VC, Yu W, Berman DM, Jenuwein T, Pruitt K, Sharkis SJ, Watkins DN, Herman JG, Baylin SB. A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. Nat Genet 2007; 39: 237-42.